BIOMARIN PHARMACEUTICAL INC Repayments of Convertible Debt
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Repayments of Convertible Debt of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfConvertibleDebt · last filed 2026-02-26
- BIOMARIN PHARMACEUTICAL INC repayments of convertible debt for the quarter ending 2025-12-31 was $0.00.
- BIOMARIN PHARMACEUTICAL INC repayments of convertible debt for the quarter ending 2024-12-31 was $0.00.
- BIOMARIN PHARMACEUTICAL INC repayments of convertible debt for the quarter ending 2023-12-31 was $0.00.
- BIOMARIN PHARMACEUTICAL INC repayments of convertible debt for the quarter ending 2015-03-31 was $163.00K.
- BIOMARIN PHARMACEUTICAL INC repayments of convertible debt for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- BIOMARIN PHARMACEUTICAL INC repayments of convertible debt for fiscal 2024 was $494.99M.
- BIOMARIN PHARMACEUTICAL INC repayments of convertible debt for fiscal 2023 was $0.00.
- BIOMARIN PHARMACEUTICAL INC repayments of convertible debt for fiscal 2022 was $0.00.
| Period end | Repayments of Convertible Debt 3 month | Repayments of Convertible Debt 6 month | Repayments of Convertible Debt 9 month | Repayments of Convertible Debt 12 month | Repayments of Convertible Debt 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $0.00 10-Q · filed 2025-10-28 | ||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $494.99M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $494.99M 10-Q · filed 2025-10-28 | ||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $0.00 10-Q · filed 2024-10-31 | ||||
| 2022-12-31 | $0.00 10-K · filed 2025-02-24 | ||||
| 2021-12-31 | $0.00 10-K · filed 2023-02-27 | ||||
| 2020-12-31 | $374.99M 10-K · filed 2023-02-27 | ||||
| 2019-12-31 | $0.00 10-K · filed 2022-02-25 | ||||
| 2018-12-31 | $374.95M 10-K · filed 2021-02-26 | ||||
| 2017-12-31 | $26.00K 10-K · filed 2020-02-27 | ||||
| 2016-12-31 | $0.00 10-K · filed 2019-02-28 | ||||
| 2015-12-31 | $163.00K 10-K · filed 2016-02-29 | ||||
| 2015-03-31 | $163.00K 10-Q · filed 2015-05-05 | $163.00K derived: sum of 2 quarters · filed 2016-02-29 | $163.00K derived: sum of 3 quarters · filed 2016-02-29 | $837.00K derived: sum of 4 quarters · filed 2016-02-29 | |
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $0.00 derived: sum of 2 quarters · filed 2016-02-29 | $674.00K derived: sum of 3 quarters · filed 2016-02-29 | $674.00K 10-K · filed 2016-02-29 | |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-28 | $674.00K derived: sum of 2 quarters · filed 2014-10-28 | $674.00K 10-Q · filed 2014-10-28 | $1.49M derived: sum of 4 quarters · filed 2016-02-29 | |
| 2014-06-30 | $674.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31 | $674.00K 10-Q · filed 2014-07-31 | $1.49M derived: sum of 3 quarters · filed 2016-02-29 | $3.22M derived: sum of 4 quarters · filed 2016-02-29 | |
| 2014-03-31 | $0.00 10-Q · filed 2014-05-02 | $813.00K derived: sum of 2 quarters · filed 2016-02-29 | $2.54M derived: sum of 3 quarters · filed 2016-02-29 | $2.54M derived: sum of 4 quarters · filed 2016-02-29 | |
| 2013-12-31 | $813.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $2.54M derived: sum of 2 quarters · filed 2016-02-29 | $2.54M derived: sum of 3 quarters · filed 2016-02-29 | $12.96M 10-K · filed 2016-02-29 | |
| 2013-09-30 | $1.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-28 | $1.73M derived: sum of 2 quarters · filed 2014-10-28 | $12.15M 10-Q · filed 2014-10-28 | $12.15M derived: sum of 4 quarters · filed 2014-10-28 | |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31 | $10.42M 10-Q · filed 2014-07-31 | $10.42M derived: sum of 3 quarters · filed 2014-07-31 | $10.42M derived: sum of 4 quarters · filed 2014-07-31 | |
| 2013-03-31 | $10.42M 10-Q · filed 2014-05-02 | $10.42M derived: sum of 2 quarters · filed 2014-05-02 | $10.42M derived: sum of 3 quarters · filed 2014-05-02 | $10.42M derived: sum of 4 quarters · filed 2014-05-02 | |
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-26 | $0.00 derived: sum of 2 quarters · filed 2014-02-26 | $0.00 derived: sum of 3 quarters · filed 2014-02-26 | $0.00 10-K · filed 2014-02-26 | |
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-28 | $0.00 derived: sum of 2 quarters · filed 2013-10-28 | $0.00 10-Q · filed 2013-10-28 | -$338.00K derived: sum of 4 quarters · filed 2014-02-26 | |
| 2012-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-29 | $0.00 10-Q · filed 2013-07-29 | -$338.00K derived: sum of 3 quarters · filed 2014-02-26 | ||
| 2012-03-31 | $0.00 10-Q · filed 2013-04-29 | -$338.00K derived: sum of 2 quarters · filed 2014-02-26 | |||
| 2011-12-31 | -$338.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-26 | $1.90M 10-K · filed 2014-02-26 | $2.23M 10-K · filed 2012-02-22 | ||
| 2011-09-30 | $2.23M 10-Q · filed 2012-10-29 | ||||
| 2010-12-31 | $14.08M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $14.08M 10-K · filed 2013-02-26 | |||
| 2010-09-30 | $0.00 10-Q · filed 2011-10-31 | ||||
| 2009-12-31 | $0.00 10-K · filed 2012-02-22 | ||||
| 2008-12-31 | $0.00 10-K · filed 2011-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |